Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07777263 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT07777263 · ClinicalTrials.gov record · last posted 2026-08-20

ADT De-escalation in Selected High-Risk Prostate Cancer Patients (ADaPPt Trial) a GROUQ Led PCS Study (PCS XIV)

StatusNot Yet Recruiting
PhasePhase 3
Started2026-10
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
High-risk prostate cancer is usually treated with a combination of radiation therapy and hormone therapy (ADT). Radiation destroys cancer cells, while ADT lowers testosterone, a hormone that prostate cancer cells need to grow. Together, these treatments help control the cancer. ADT is usually given for 18 to 24 months, but it can cause side effects that may affect quality of life. Some people with high-risk prostate cancer may do just as well with a shorter course of ADT. This study will identify people who are most likely to benefit from shorter treatment using imaging scans and tumor tests. It will then evaluate whether a shorter course of ADT works as well as the standard treatment while reducing long-term side effects.
Trial Details
NCT Number NCT07777263
Lead Sponsor Dr. Tamim Niazi
Conditions High Risk Prostate Cancer
Enrollment 600 participants
Start Date 2026-10
Primary Completion 2035-10 (estimated)
Study Completion 2040-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-20